Sunko Ink Co (1721) Fair Value & Analysis
Basic Materials · TW · Market cap 4.3B TWD
Fair value as of: Jun 24, 2026
Analysis
Sunko Ink Co (1721) currently trades at 25.25 TWD, while our model-based Fair Value estimate is 10.54 TWD — implying the stock looks roughly 58.3% overvalued today. We read business quality at 95/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Sunko Ink Co., Ltd. engages in the manufacture and trading of chemicals and industrial materials in Taiwan, the United States, Asia, Europe, and internationally. The company offers polymer elastomers, plant protection medicines, electronic chemicals, rubber and plastic additives, PVC and PU artificial leather surface treatment agents, and cross linking agents. It also provides agrochemicals; fine chemicals, such as curing agent, non-halogenated flame retardant, reducing agent, and antioxidant; PU based surface treating agent, polymer-TPU, and polymer-TPV; and UV absorbers. In addition, the company engages in the wholesale of chemical solvents, industrial additives, and other chemical raw materials or with derivatives. Its products are used in various applications, such as petrochemicals, rubber plastics, footwear, and cosmetics. Sunko Ink Co., Ltd. was incorporated in 1974 and is based in Taichung, Taiwan.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Sunko Ink Co (1721) undervalued?
What is the fair value of 1721?
What is the quality score of 1721?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.